1. Home
  2. AAUC vs MLYS Comparison

AAUC vs MLYS Comparison

Compare AAUC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allied Gold Corporation

AAUC

Allied Gold Corporation

HOLD

Current Price

$21.23

Market Cap

3.1B

Sector

N/A

ML Signal

HOLD

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$24.88

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAUC
MLYS
Founded
N/A
2019
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.5B
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
AAUC
MLYS
Price
$21.23
$24.88
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $48.67
AVG Volume (30 Days)
304.4K
★ 1.2M
Earning Date
05-19-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 37.43
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$94.92
N/A
Revenue Next Year
$27.93
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.60
$22.30
52 Week High
$32.20
$47.65

Technical Indicators

Market Signals
Indicator
AAUC
MLYS
Relative Strength Index (RSI) 43.51 37.90
Support Level $20.55 $22.36
Resistance Level $24.82 $31.36
Average True Range (ATR) 0.72 1.44
MACD -0.14 -0.45
Stochastic Oscillator 21.70 2.90

Price Performance

Historical Comparison
AAUC
MLYS

About AAUC Allied Gold Corporation

Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa, where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, develops new mines, advances its exploration properties, and targets other consolidation opportunities, with a focus on Africa.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: